Y-Mabs Therapeutics Overview
Latest ROE for Y-Mabs Therapeutics: -25.4% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-25.40%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for YMAB is -25.4%. That is below the Healthcare sector average of 29.33%. Investors often review this figure alongside Y-Mabs Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, YMAB currently prints -25.4% for ROE, while the sector average sits near 29.33%. That is roughly 186.6% below the sector mean. Large gaps often invite a closer look at Y-Mabs Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Y-Mabs Therapeutics converts resources into returns. At -25.4%, YMAB may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting YMAB's ROE (-25.4%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Y-Mabs Therapeutics's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
